Verastem | VSTM - Assets


Verastem reported $227.81M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Alaunos Therapeutics USD 1.52M 367K Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Curis USD 29.69M 9.72M Mar/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Laboratory Of America USD 18.92B 392.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Verastem USD 227.81M 18.63M Mar/2026